Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126694942 | 12669494 | 2 | F | 20160817 | 20160819 | 20160829 | EXP | US-ACTELION-A-US2016-140789 | ACTELION | 80.00 | YR | E | F | Y | 0.00000 | 20160829 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126694942 | 12669494 | 1 | PS | TRACLEER | BOSENTAN | 1 | Oral | 125 MG, UNK | NP014P0201 | 21290 | 125 | MG | TABLET | ||||||
| 126694942 | 12669494 | 2 | C | RIOCIGUAT | RIOCIGUAT | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126694942 | 12669494 | 1 | Pulmonary arterial hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126694942 | 12669494 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126694942 | 12669494 | Furuncle | |
| 126694942 | 12669494 | Joint effusion | |
| 126694942 | 12669494 | Oedema peripheral | |
| 126694942 | 12669494 | Skin infection | |
| 126694942 | 12669494 | Skin neoplasm excision | |
| 126694942 | 12669494 | Squamous cell carcinoma of skin | |
| 126694942 | 12669494 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126694942 | 12669494 | 1 | 20150707 | 0 |